Contract Development And Manufacturing Organizations (CDMO)

Photo

Symeres Acquires DGr Pharma

CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.

Photo

Marianne Späne to Leave Siegfried Management

The pharmaceutical service provider Siegfried has announced changes to its management team. Marianne Späne, who has been with the Swiss CDMO since 2004 and has held the position of Chief Business Officer since the beginning of 2020, is moving to the Board of Directors of the subsidiary Dinamiqs.

Photo

Resilience Will Close 6 of its 10 Plants

Resilience recently shared that capacity expansions have exceeded current industry demand. As a result, Resilience has begun consolidating its operations and streamlining its business strategy.

Photo

Bionova Licenses Technologies from ATUM

Bionova Scientific, an Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has licensed ATUM’s proprietary Leap-In Transposase transposon-based gene delivery and its miCHO cell line development technologies.

Photo

Fujifilm Diosynth Biotechnologies & Regeneron Sign Manufacturing Agreement

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.

343 more articles

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.